Pharmaceuticals News and Research

RSS

D-ATLAS to map the prevalence and costs associated with type 2 diabetes launched

Pinpointing the prevalence and cost of type 2 diabetes and now, the prevalence of obesity (Body Mass Index [BMI] of 30 or greater), is just a mouse click away thanks to a Web-based tool developed by the National Minority Quality Forum (NMQF).

1 Dec 2009

Genetic Analysis introduces GA-map microarray test for screening of infant gut microbiota

Genetic Analysis AS, the molecular diagnostics company, has launched its GA-map™ microarray test for high throughput screening of infant gut microbiota. At the recent Sackler Colloquium on Microbes and Health in the US, the company presented data from evaluation screens that show its potential as a tool for probing the mechanisms of disease in conditions associated with the gut flora.

1 Dec 2009

HTDS finalizes contract details with Indian pharmaceutical company

Hard to Treat Diseases' (HTDS; http://www.htdsmedical.com/) operating subsidiary Mellow Hope finalized contract details with one of the largest manufacturer of intravenous medication in India.

1 Dec 2009

Changda International Holdings receives first commercial order for Thiophene from Sanofi Aventis

Changda International Holdings, the Weifang based specialty chemicals manufacturer has received a first commercial order for it product Thiophene from Sanofi Aventis (NYSE: SNY), the French pharmaceutical multinational.

1 Dec 2009

Use of BSGI as adjunct imaging modality for diagnosing breast cancer demonstrated

Dr. Jessica Torrente, Assistant Professor of Radiology at George Washington University Medical Center in Washington, D.C., demonstrated the integration and use of Breast-Specific Gamma Imaging (BSGI) in clinical practice as an adjunct imaging modality for the diagnosis of breast cancer today at the annual meeting of the Radiological Society of North America (RSNA).

1 Dec 2009

Mechanism blocking HIV-1 from entering cells identified

Publishing in PLoS Pathogens, researchers at from the Kimmel Cancer Center at Jefferson have found a novel mechanism by which drugs block HIV-1 from entering host cells.

1 Dec 2009

Sanofi-Aventis Canada and Intelliject sign license agreement

Sanofi-aventis Canada has announced a licensing agreement with Intelliject, Inc. for a novel epinephrine auto injector for the emergency treatment of allergic reactions (anaphylaxis) in North America (U.S and Canada).

1 Dec 2009

Refuse to file letter on NDA for Cladribine Tablets issued to EMD Serono

EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, announced today that it received a refuse to file letter from the US Food and Drug Administration (FDA) on the New Drug Application (NDA) for Cladribine Tablets, EMD Serono's proprietary investigational oral formulation of cladribine, as a therapy for relapsing forms of multiple sclerosis (MS).

1 Dec 2009

Intelliject announces an exclusive license with sanofi-aventis for epinephrine auto-injector

Intelliject, Inc. today announced an exclusive license with sanofi-aventis U.S. for a novel epinephrine auto-injector, in the U.S. and Canada territory. Under the license, sanofi-aventis U.S. shall be responsible for manufacturing and commercialization.

1 Dec 2009

Brain monitors help avoid postop dementia from routine anesthesia over-medication

To date, hospitals have not found a billing code that insurers will reimburse them for the $20 cost of the disposable sensor for your brain monitor for 'going under' for surgery.

1 Dec 2009

University of Navarra Hospital launches clinical trials to assess the efficacy of immunotherapy treatment

The University of Navarra Hospital has launched a series of clinical trials in order to assess the efficacy of an immunotherapy treatment. This approach involves the application of personalised vaccines -produced from healthy and tumour cells from the patient him or herself- and designed to combat glioblastomas, one of the most aggressive and frequent malignant tumours.

1 Dec 2009

ChemGenex Pharmaceuticals to present updated clinical data from its clinical trials with Omapro

ChemGenex Pharmaceuticals Limited announced today that updated clinical data from several of its clinical trials with Omapro™ (omacetaxine mepesuccinate) will be presented at the upcoming 51st American Society of Hematology Annual Meeting in New Orleans, Louisiana.

1 Dec 2009

USPTO issues Notice of Allowance for Titan Pharmaceuticals' Probuphine patent application

Titan Pharmaceuticals, Inc today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Titan’s United States patent application directed to the use of Probuphine for the treatment of opiate addiction.

1 Dec 2009

Xybion completes the acquisition of all operating assets of Amadeus Solutions

Xybion Corporation announced today that through the creation of a wholly owned Quebec Corporation, Services Informatiques Xybion, it has completed the acquisition of all operating assets of Quebec City based Amadeus Solutions, a leader in the development of enterprise governance, risk, compliance and quality management software solutions, from DECIMAL, a corporate performance management organization headquartered in Montreal.

1 Dec 2009

BSGI proves to be an effective adjunct imaging modality for detecting DCIS

Breast-Specific Gamma Imaging (BSGI) has been proven to be a highly sensitive imaging technique for the detection of ductal carcinoma in situ (DCIS), a difficult to diagnose breast cancer. BSGI is a molecular breast imaging technique that can see lesions independent of tissue density and discover very early stage cancers.

30 Nov 2009

GLUMETZA patent infringement lawsuit against Lupin

Depomed, Inc. today announced that it has filed a lawsuit in the United States District Court for the Northern District of California against Lupin Limited and its wholly-owned subsidiary, Lupin Pharmaceuticals, Inc., for infringement of the patents listed in the Orange Book for GLUMETZA® (metformin hydrochloride extended release tablets).

30 Nov 2009

Clinical trials of personalised vaccines to fight glioblastomas

The University of Navarra Hospital has launched a series of clinical trials in order to assess the efficacy of an immunotherapy treatment. This approach involves the application of personalised vaccines —produced from healthy and tumour cells from the patient him or herself— and designed to combat glioblastomas, one of the most aggressive and frequent malignant tumours.

30 Nov 2009

BioMarin Pharmaceutical receives FDA orphan drug designation for 3,4-DAP

BioMarin Pharmaceutical Inc. announced today that the Food and Drug Administration (FDA) has granted orphan drug designation for 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS). 3,4-DAP has previously received orphan drug designation in the E.U.

30 Nov 2009

Bayer Healthcare Pharmaceuticals commences enrollment in florbetaben Phase III clinical trials

Today at the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Bayer HealthCare Pharmaceuticals Inc. announced the enrollment of the first patient in an international Phase III clinical trial to evaluate the efficacy and safety of florbetaben (BAY 94-9172) PET imaging in the detection of beta-Amyloid plaques in the brain, which are a pathological hallmark of Alzheimer's disease.

30 Nov 2009

Kiadis Pharma commences enrollment in multinational ATIR study

Biopharmaceutical company Kiadis Pharma announces today that the first patients have been enrolled in its multinational registration clinical trial with ATIR(TM). The study is designed to show reduction in transplant related mortality (TRM) after one year following an allogeneic stem cell transplantation with a mismatched (haplo-identical) donor in blood cancer patients eligible for an allogeneic stem cell transplantation but without having a matched donor available.

30 Nov 2009

Pharmaceuticals News and Research

D-ATLAS to map the prevalence and costs associated with type 2 diabetes launched

Genetic Analysis introduces GA-map microarray test for screening of infant gut microbiota

HTDS finalizes contract details with Indian pharmaceutical company

Changda International Holdings receives first commercial order for Thiophene from Sanofi Aventis

Use of BSGI as adjunct imaging modality for diagnosing breast cancer demonstrated

Mechanism blocking HIV-1 from entering cells identified

Sanofi-Aventis Canada and Intelliject sign license agreement

Refuse to file letter on NDA for Cladribine Tablets issued to EMD Serono

Intelliject announces an exclusive license with sanofi-aventis for epinephrine auto-injector

Brain monitors help avoid postop dementia from routine anesthesia over-medication

University of Navarra Hospital launches clinical trials to assess the efficacy of immunotherapy treatment

ChemGenex Pharmaceuticals to present updated clinical data from its clinical trials with Omapro

USPTO issues Notice of Allowance for Titan Pharmaceuticals' Probuphine patent application

Xybion completes the acquisition of all operating assets of Amadeus Solutions

BSGI proves to be an effective adjunct imaging modality for detecting DCIS

GLUMETZA patent infringement lawsuit against Lupin

Clinical trials of personalised vaccines to fight glioblastomas

BioMarin Pharmaceutical receives FDA orphan drug designation for 3,4-DAP

Bayer Healthcare Pharmaceuticals commences enrollment in florbetaben Phase III clinical trials

Kiadis Pharma commences enrollment in multinational ATIR study

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring